Description of the medicine: Telmisartan (Telmisartan)
4′-Methyl-6 - [(1-methyl-2-benzimidazolyl) -2-propyl-1-benzimidazolyl] -2-biphenylcarboxylic acid.
Synonyms: Mikardis, Prytor, Micardis, Prytor.
White or colorless crystalline powder. It is practically insoluble in water, partially soluble in strong acids and soluble in strong alkalis.
It is well absorbed in the gastrointestinal tract, bioavailability is 40-60% (the effect of the "first passage" through the liver), C max - 1 hour, T Ѕ - 20-30 hours; It is excreted mainly with bile.
Apply with arterial hypertension.
Assign inside 0.04 g (40 mg), if necessary 0.08 g (80 mg) once a day.
The antihypertensive effect develops 3 hours after administration and persists for more than 24 hours; stable clinical effect is achieved after 4-8 weeks of course treatment.
Side effects (headache, dizziness, dyspepsia, nausea, diarrhea, cough, abdominal, chest and lower back pain, hyperuricemia, etc.) are rare.
The drug is contraindicated in severe violations of the liver and kidneys, during pregnancy and lactation.
Release form: tablets on 0,04 and 0,08 g (N. 7, 14).
Storage: List B.